ADMA Biologics Q1 Earnings, Revenue Rise; Shares Fall After Hours

MT Newswires Live
05/08

ADMA Biologics (ADMA) reported Q1 earnings late Wednesday of $0.11 per diluted share, up from $0.08 a year earlier.

Three analysts polled by FactSet expected $0.15.

Revenue in the three months ended March 31 rose to $114.8 million from $81.9 million a year earlier. Three analysts surveyed by FactSet expected $116.4 million.

The company raised 2025 revenue guidance to over $500 million from over $490 million and boosted the 2026 forecast to over $625 million from $605 million.

Three analysts expect $496.1 million this year and $629.7 million in 2026.

The board authorized a stock repurchase program of up to $500 million

The company's shares fell 4.7% in after-hours trading.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10